早期置入经颈静脉肝内门体分流术治疗复发性腹水的成本效益分析
研究采用马尔可夫模型,从支付方视角比较早期经颈静脉肝内门体分流术(TIPS)与连续大量腹腔穿刺放液加白蛋白输注(LVP+A)治疗肝硬化复发性腹水的成本效益。基础分析显示早期TIPS成本更高(22770美元 vs 19180美元)但QALY更高(0.73 vs 0.65),ICER为46310美元/QALY。概率敏感性分析中TIPS在59.1%的模拟中为最优策略,作者认为早期TIPS对特定患者具有成本效益,应考虑作为一线治疗选择。
要点
- 早期TIPS较LVP+A成本更高(22770美元 vs 19180美元)但QALY更高(0.73 vs 0.65)。
- 基础分析ICER为46310美元/QALY,低于100000美元/QALY的成本效益阈值。
- 概率敏感性分析中TIPS置入在59.1%的模拟中为最优策略。
核心结论
- 基于马尔可夫模型分析,早期置入TIPS似乎是对特定肝硬化复发性腹水患者具有成本效益的策略。
- 作者认为对特定患者应早期考虑TIPS置入并作为一线治疗选择。
研究设计与样本
- 研究采用马尔可夫模型,从支付方视角对肝硬化复发性腹水患者进行假设队列分析。
- 模型数据来源于2012年至2018年收集的出版物和国家数据库。
- 比较策略为早期TIPS置入与连续大量腹腔穿刺放液加白蛋白输注(LVP+A)。
- 早期TIPS定义为过去3周内2次LVP且过去3个月内少于6次LVP。
- 进行了单因素、双因素和概率敏感性分析,ICER低于100000美元/QALY被视为具有成本效益。
主要发现
- 基础分析中早期TIPS成本为22770美元,高于LVP+A的19180美元。
- 早期TIPS的QALY为0.73,高于LVP+A的0.65。
- 基础分析ICER为46310美元/QALY。
- 结果对无并发症TIPS置入和移植成本、LVP+A需求、移植概率和失代偿QALY敏感。
- 概率敏感性分析中TIPS置入在59.1%的模拟中为最优策略。
关键数值与推荐
- ICER低于100000美元/QALY被视为具有成本效益。
- 早期TIPS定义为过去3周内2次LVP且过去3个月内少于6次LVP。
临床怎么用
- 作者认为对特定肝硬化复发性腹水患者应早期考虑TIPS置入并作为一线治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Treatment options for recurrent ascites resulting from decompensated cirrhosis include serial large-volume paracentesis and albumin infusion (LVP+A) or insertion of a transjugular intrahepatic portosystemic shunt (TIPS). Insertion of TIPSs with covered stents during early stages of ascites (early TIPS, defined as 2 LVPs within the past 3 weeks and <6 LVPs in the prior 3 months) significantly improves chances of survival and reduces complications of cirrhosis compared with LVP+A. However, it is not clear if TIPS insertion is cost effective in these patients. METHODS: We developed a Markov model using the payer perspective for a hypothetical cohort of patients with cirrhosis with recurrent ascites receiving early TIPSs or LVP+A using data from publications and national databases collected from 2012 to 2018. Projected outcomes included quality-adjusted life-year (QALY), costs (2017 US dollars), and incremental cost-effectiveness ratios (ICERs; $/QALY). Sensitivity analyses (1-way, 2-way, and probabilistic) were conducted. ICERs less than $100,000 per QALY were considered cost effective. RESULTS: In base-case analysis, early insertion of TIPS had a higher cost ($22,770) than LVP+A ($19,180), but also increased QALY (0.73 for early TIPSs and 0.65 for LVP+A), resulting in an ICER of $46,310/QALY. Results were sensitive to cost of uncomplicated TIPS insertion and transplant, need for LVP+A, probability of transplant, and decompensated QALY. In probabilistic sensitivity analysis, TIPS insertion was the optimal strategy in 59.1% of simulations. CONCLUSIONS: Based on Markov model analysis, early placement of TIPSs appears to be a cost-effective strategy for management of specific patients with cirrhosis and recurrent ascites. TIPS placement should be considered early and as a first-line treatment option for select patients.
引用
- Shen NT, Schneider Y, Congly SE, et al. Cost Effectiveness of Early Insertion of Transjugular Intrahepatic Portosystemic Shunts for Recurrent Ascites. Clin Gastroenterol Hepatol. 2018. PMID: 29609068. doi:10.1016/j.cgh.2018.03.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。